FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282960722> ?p ?o ?g. }

• W4282960722 endingPage "4024" @default.
• W4282960722 startingPage "4024" @default.
• W4282960722 abstract "Abstract Mitogen-activated protein kinase (MAPK) pathway alterations comprise some of the most frequent mutations in newly diagnosed acute myeloid leukemia (AML). Moreover, MAPK pathway alterations are also emerging as potential mechanisms of resistance to targeted therapy in AML including FLT3 inhibitors and venetoclax. In an ex vivo pharmacologic analysis of primary AML samples, sensitivity to the MEK inhibitor selumetinib (ARRY-142886) was enriched in patient samples resistant to venetoclax. Clinical activity of MAPK pathway inhibitors such as selumetinib has been explored in AML but monotherapy responses were modest. Another MEK inhibitor, cobimetinib, is currently being tested in combination with venetoclax in AML. We sought to understand whether combining selumetinib with BH3 mimetics such as venetoclax would improve efficacy in AML models. We evaluated combination activity of selumetinib plus venetoclax or the MCL1 inhibitor AZD5991 in a panel of AML cell lines. Cells were exposed to a 6x6 matrix of both agents for 72hrs and then viability assessed using CellTiter-Glo. Combination benefit was assessed using highest single agent (HSA) analysis. Selumetinib+AZD5991 demonstrated strong combination benefit (HSA score &gt;0.1, Emax &gt;0.5) in 4/19 AML cell lines. Selumetinib+venetoclax showed strong combination activity in 6/19 lines. Three lines showed benefit with both combinations. Many of these cell lines harbor MAPK pathway mutations including OCI-AML5 (SOS1N233Y, NF1K1385R), ML-2 (KRASA146T), HL-60 (NRASQ61L), and Nomo-1 (KRASG13D). Selumetinib treatment also led to robust BIM induction in vitro. Nomo-1 xenografts were evaluated for in vivo sensitivity to venetoclax (100 mg/kg qd PO), 5-azacytidine (1mg/kg BID q8h 3days on/4days off IP), AZD5991 (30mpk bid q2h qw IV), selumetinib (10 mg/kg bid q8h PO), as well as combinations of venetoclax+5-aza, AZD5991+selumetinib, and venetoclax+selumetinib. Venetoclax and venetoclax+5-aza treatment were ineffective. Selumetinib monotherapy led to 63% tumor growth inhibition (TGI) but tumors eventually grew out through treatment. The combination of selumetinib+venetoclax slightly improved efficacy (81% TGI) but markedly delayed tumor outgrowth (selumetinib monotherapy arm reached mean tumor volume &gt;1000 mm3 on day 17, selumetinib+venetoclax reached average of ~966 mm3 on day 28). Reducing venetoclax dose (30mg/kg qd) or frequency (100mg/kg 3days on/4days off) maintained most of the combination efficacy. Selumetinb+AZD5991 also strongly improved efficacy compared to either monotherapy (88% TGI, mean tumor volume did not exceed ~400mm3 by day 28). Together these data suggest potential for combining MEK inhibitors with BH3 mimetics in AML. Work is ongoing to further understand how scheduling impacts combination efficacy, evaluate the triple combination of selumetinib+BH3 mimetic+azacytidine, and assess efficacy in disseminated models. Citation Format: Courtney L. Andersen, Azadeh Cheraghchi-Bashi, Patricia Jaaks, Elizabeth A. Coker, Kathleen Burke, Justin Cidado, Paul Smith, Corinne Reimer, Raoul Tibes, Mathew Garnett, Jerome Mettetal. Combining selumetinib with BH3 mimetics enhances activity in MAPK-activated acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4024." @default.
• W4282960722 created "2022-06-17" @default.
• W4282960722 creator A5008327190 @default.
• W4282960722 creator A5008571021 @default.
• W4282960722 creator A5018041025 @default.
• W4282960722 creator A5022581351 @default.
• W4282960722 creator A5028843362 @default.
• W4282960722 creator A5031794249 @default.
• W4282960722 creator A5037780629 @default.
• W4282960722 creator A5043764611 @default.
• W4282960722 creator A5061267813 @default.
• W4282960722 creator A5065531168 @default.
• W4282960722 creator A5085472676 @default.
• W4282960722 date "2022-06-15" @default.
• W4282960722 modified "2023-09-24" @default.
• W4282960722 title "Abstract 4024: Combining selumetinib with BH3 mimetics enhances activity in MAPK-activated acute myeloid leukemia" @default.
• W4282960722 doi "https://doi.org/10.1158/1538-7445.am2022-4024" @default.
• W4282960722 hasPublicationYear "2022" @default.
• W4282960722 type Work @default.
• W4282960722 citedByCount "0" @default.
• W4282960722 crossrefType "journal-article" @default.
• W4282960722 hasAuthorship W4282960722A5008327190 @default.
• W4282960722 hasAuthorship W4282960722A5008571021 @default.
• W4282960722 hasAuthorship W4282960722A5018041025 @default.
• W4282960722 hasAuthorship W4282960722A5022581351 @default.
• W4282960722 hasAuthorship W4282960722A5028843362 @default.
• W4282960722 hasAuthorship W4282960722A5031794249 @default.
• W4282960722 hasAuthorship W4282960722A5037780629 @default.
• W4282960722 hasAuthorship W4282960722A5043764611 @default.
• W4282960722 hasAuthorship W4282960722A5061267813 @default.
• W4282960722 hasAuthorship W4282960722A5065531168 @default.
• W4282960722 hasAuthorship W4282960722A5085472676 @default.
• W4282960722 hasConcept C126322002 @default.
• W4282960722 hasConcept C143998085 @default.
• W4282960722 hasConcept C184235292 @default.
• W4282960722 hasConcept C185592680 @default.
• W4282960722 hasConcept C207001950 @default.
• W4282960722 hasConcept C2776087337 @default.
• W4282960722 hasConcept C2777938653 @default.
• W4282960722 hasConcept C2778461978 @default.
• W4282960722 hasConcept C2778729363 @default.
• W4282960722 hasConcept C2779675984 @default.
• W4282960722 hasConcept C2781249067 @default.
• W4282960722 hasConcept C502942594 @default.
• W4282960722 hasConcept C54355233 @default.
• W4282960722 hasConcept C55493867 @default.
• W4282960722 hasConcept C57074206 @default.
• W4282960722 hasConcept C71924100 @default.
• W4282960722 hasConcept C86803240 @default.
• W4282960722 hasConcept C98274493 @default.
• W4282960722 hasConceptScore W4282960722C126322002 @default.
• W4282960722 hasConceptScore W4282960722C143998085 @default.
• W4282960722 hasConceptScore W4282960722C184235292 @default.
• W4282960722 hasConceptScore W4282960722C185592680 @default.
• W4282960722 hasConceptScore W4282960722C207001950 @default.
• W4282960722 hasConceptScore W4282960722C2776087337 @default.
• W4282960722 hasConceptScore W4282960722C2777938653 @default.
• W4282960722 hasConceptScore W4282960722C2778461978 @default.
• W4282960722 hasConceptScore W4282960722C2778729363 @default.
• W4282960722 hasConceptScore W4282960722C2779675984 @default.
• W4282960722 hasConceptScore W4282960722C2781249067 @default.
• W4282960722 hasConceptScore W4282960722C502942594 @default.
• W4282960722 hasConceptScore W4282960722C54355233 @default.
• W4282960722 hasConceptScore W4282960722C55493867 @default.
• W4282960722 hasConceptScore W4282960722C57074206 @default.
• W4282960722 hasConceptScore W4282960722C71924100 @default.
• W4282960722 hasConceptScore W4282960722C86803240 @default.
• W4282960722 hasConceptScore W4282960722C98274493 @default.
• W4282960722 hasIssue "12_Supplement" @default.
• W4282960722 hasLocation W42829607221 @default.
• W4282960722 hasOpenAccess W4282960722 @default.
• W4282960722 hasPrimaryLocation W42829607221 @default.
• W4282960722 hasRelatedWork W2063614197 @default.
• W4282960722 hasRelatedWork W2080686146 @default.
• W4282960722 hasRelatedWork W2103749352 @default.
• W4282960722 hasRelatedWork W2126570100 @default.
• W4282960722 hasRelatedWork W2141202463 @default.
• W4282960722 hasRelatedWork W2505698301 @default.
• W4282960722 hasRelatedWork W2906115228 @default.
• W4282960722 hasRelatedWork W3083144001 @default.
• W4282960722 hasRelatedWork W4362493042 @default.
• W4282960722 hasRelatedWork W4362495258 @default.
• W4282960722 hasVolume "82" @default.
• W4282960722 isParatext "false" @default.
• W4282960722 isRetracted "false" @default.
• W4282960722 workType "article" @default.